As the primary action of the GG constituent glycyrrhizin is to inhibit 11betaHSD2 and (directly or indirectly) TLR4, this principal may emerge as a new target for a definable subgroup of patients with depression, if confirmed in future research. The gene discussed is TLR4; the disease is depressive symptom measurement.